AzTrials
AzTrials

To Set up NTM Stimulation Test Foar Diagnosing NTM Pulmonary Infectionon.NCT01676142

Establishing a Diagnostic Test for Non-tuberculous Mycobacteria Lung Infection Using Non-tuberculous Mycobacteria Antigen Stimulation Test: From Immune Base, Standardized Setup to Validation

An observational study of To Set up NTM Stimulation Test Foar Diagnosing NTM Pulmonary Infectionon., run by National Taiwan University Hospital at 1 site in Taiwan.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

1. To compare TLR-2 expression of peripheral blood mononuclear cells and serum downstream cytokines in those with MAC or MAB pulmonary infection and those with MAC or MAB pulmonary colonization and controls. 2. Read more about this study

Who is it for?
Ages 18 years and older
How many people
200 participants
Where
1 siteTaiwan
Study dates
Jan 2011to Jan 2014
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: 1. Patients with NTM pulmonary infection: diagnosed by NTM guidelines by American Thoracic Society(ATS) 2. Patients with NTM pulmonary colonization: Patients are not fulfilling the ATS diagnostic criteria but having at least one set of positive sputum for NTM (colonization). 3. Patients have pulmonary infiltrates, not related by NTM: three sets of respiratory specimens that are negative for NTM.

Who may be able to join

  • Age ≥ 18 years
  • A patient has at least 3 sets of respiratory specimen for mycobacterial culture.

Who cannot join

  • Age younger than 18 years.
  • Patients who have pregnancy.
  • Patients who have acquired immunodeficiency syndrome
  • Patients who have bleeding tendency which can not tolerate venous puncture such as hemophilia, thrombocytopenia.
  • In NTM infection group, patients having received anti-NTM treatment for one week will be excluded.

Trial locations and contacts

1 site in 1 country.

Chin-Chung Shu, MD contact

886972653087

chinchungshu@ntu.edu.tw

Taiwan1 site, 1 recruiting
  • National Taiwan University Hospital

    Taipei, 100

    Chin-Chung Shu, MD, 886972653087

    Chin-Chung Shu, MD

    Recruiting

Other trials in Taiwan

About this study

  1. To compare TLR-2 expression of peripheral blood mononuclear cells and serum downstream cytokines in those with MAC or MAB pulmonary infection and those with MAC or MAB pulmonary colonization and controls.
  2. To investigate the response of TLR-2 expression and cytokines activation to NTM stimulation test in patients with MAC or MAB pulmonary infection and colonization and controls.
  3. To validate the NTM stimulation test for NTM pulmonary infection.
Read the detailed description

The increase of nontuberculous mycobacteria lung infection Nontuberculous mycobacteria lung infection (NTM-LD) becomes an important clinical concern [1] because the rate of NTM infection has increased over the past ten years [2-3]. According to a study in Taiwan, NTM-LD increased from 1.26 to 7.94 per 100,000 inpatients/year during 2000 to 2008 [2]. The reasons for this increase are not readily clear, but could be related to the growth in numbers of the acquired immunocompromised population and advances of technique for mycobacterial culture [4-7]. Among the NTM infection in Taiwan, Mycobacterium avium complex (MAC) and M. abscessus (MAB) were most frequently isolated [2].

The difficulty in early diagnosing and confirming true NTM-LD However, NTM exists in the environment ubiquitously, so the relevance (true disease patient number over the number of patients with disease or just colonization) is far less than 100% and varied in different NTM species. For example, previous studies have shown that the presence of M. kansasii and MAC had a clinical relevance around 47~70% and 35~42%, respectively [8-9]. As for MAB which is emerging pathogen worldwide, has a relevance of 33% [9]. According to contemporary NTM guidelines established by American thoracic society, NTM pulmonary infection is diagnosed by multiple criteria including microbiology of respiratory specimen and clinical findings as well as radiographic findings [1]. In microbiology criteria, two or more sets of positive sputum mycobacterial culture for the same NTM species within one year is needed.

Because NTM colonization is not uncommon in respiratory tract, diagnosis of true pulmonary NTM infection is a great challenge in clinical practice. Actually, microbiology tests for mycobacteria are neither timely nor efficient. Mycobacterial culture is time-consuming, which needed weeks to wait the results even though it's current gold standard for micro-organism identification [10]. The nucleic acid amplification method such as polymerase chain reaction could not discriminate true NTM infection and solely colonization because the micro-organism is present in both situations [11].

To early diagnose and then start treatment of NTM infection is important because NTM pulmonary infection might be rapid lethal infection in intensive care unit or in patients who had not received early proper treatment [6]. In addition, MAC or MAB which are most common in Taiwan are resistant to most of anti-tuberculosis regimen. Hence, more rapid and accurate diagnostic test should be developed [1-2, 6] The help of innate immunity in diagnosing NTM-LD The body inflammatory marker, represent our immune response, would be an indicator for differentiating true mycobacterial pulmonary infection from colonization while the first set of mycobacterial culture grew NTM [12-15]. Both interferon-gamma and tumor necrosis factor-alpha play critical roles in protective immunity to mycobacterial infections [16-17]. These responses are linked to engagement of Toll-like receptor 2 (TLR2) that is critical for mycobacterial infection [18]. However, the TLR-2 expression has not been evaluated between patients with NTM infection and colonization. According to the success of application of interferon-gamma release assay for tuberculosis detection [19], we understand the specific immune response is helpful to diagnose mycobacterial infection. We therefore focus on the expression of TLR-2 and associated downstream cytokines in our patients with MAC or MAB lung disease, which accounts the most of NTM infection [2].

The design in our study for diagnosis In order to investigate the help of host immune in diagnosing NTM pulmonary infection, we initially compare the baseline expression of TLR-2 and downstream cytokines in the MAC or MAB infected patients and colonized subjects. Then, we perform an in-vitro stimulation test using mycobacteria (MAC or MAB) for co-culturing with peripheral blood mononuclear cells of patients. The TLR-2 expression and cytokines activation will be examined after the stimulation test. We then analyze the expression difference between NTM-LD and colonization.

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01676142
Study groupRoleWhat they receive
Patients with NTM pulmonary infectionNot described
Patients with other pathogen related lung infectionNot described
Patient with NTM pulmonary colonizationNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Patients with non-tuberculous pulmonary infection

    Measured: 3 year

Secondary outcomes (1)
  1. mortality

    Measured: 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Aug 2012 (estimated)
  2. Study startJan 2011
  3. Primary completionJan 2014 (estimated)
  4. Study completionJan 2014 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01676142
Sponsor's protocol ID
201012082RC
Status last verified
Jun 2011
First submitted
28 Aug 2012
Last updated
30 Aug 2012
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of To Set up NTM Stimulation Test Foar Diagnosing NTM Pulmonary Infectionon., run by National Taiwan University Hospital at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 30 Aug 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Chin-Chung Shu, MD (886972653087, chinchungshu@ntu.edu.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Patients with non-tuberculous pulmonary infection (time frame: 3 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Aug 2012.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in